- Home
- LEGN
as 06-20-2025 4:00pm EST
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.4B | IPO Year: | 2020 |
| Target Price: | $77.09 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.34 - $60.87 | Next Earning Date: | 08-08-2025 |
| Revenue: | $728,303,000 | Revenue Growth: | 112.46% |
| Revenue Growth (this year): | 65.49% | Revenue Growth (next year): | 53.76% |
Latest Legend Biotech Corporation News
LEGN Breaking Stock News: Dive into LEGN Ticker-Specific Updates for Smart Investing
MT Newswires
17 days ago
Legend Biotech Reports 5-Year Survival Data for Carvykti in Multiple Myeloma
GlobeNewswire
18 days ago
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
Simply Wall St.
a month ago
Exploring High Growth Tech Stocks In The US This May 2025
GlobeNewswire
a month ago
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
GlobeNewswire
a month ago
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
MT Newswires
a month ago
Legend Biotech Shares Have 'Meaningful Upside' With Continued Execution, RBC Says
TipRanks
a month ago
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
MT Newswires
a month ago
Truist Securities Adjusts Legend Biotech Price Target to $71 From $88, Maintains Buy Rating
Compare LEGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LEGN Legend Biotech Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.